REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026

For research purposes only. Full disclaimer →

Research/Paper
Back to Research Library
PubMedHuman TrialHuman Subjects

Mitochondrial-Derived Peptide MOTS-c Suppresses Ovarian Cancer Progression by Attenuating USP7-Mediated LARS1 Deubiquitination.

Yin Yadong, Li Yujie, Ma Boyi, Ren Chenlu, Zhao Shuhua, Li Jia, Gong Yun, Yang Hong, Li Jibin
Advanced science (Weinheim, Baden-Wurttemberg, Germany)2024DOI: 10.1002/advs.202405620
MOTS-c

Quality Score

6/10

Citations

0

Subjects

Human

PeptideVault Analysis

Study Design

Human trial data is the most directly translatable evidence for therapeutic applications. The physiological responses observed here reflect real human biology, not extrapolations from animal models.

Our Assessment

Quality Assessment: 6/10 — This is a solidly conducted study with clear methodology and reasonable conclusions. Minor limitations exist (noted below) but don't undermine the core findings. The evidence here is reliable enough to inform both research direction and practical decision-making.

Findings in Context

The results for MOTS-c are encouraging. Critically, these findings come from human data — not animal models or in-vitro work — which makes them directly relevant to clinical applications.

On the Limitations

Every study has limitations, and being transparent about them is what separates good science from hype. Specifically: the sample size is modest, which limits statistical power and the ability to detect smaller but clinically meaningful effects. These limitations don't invalidate the findings — they define the boundaries of what we can confidently conclude.

The Takeaway

Bottom line: Decent human data on MOTS-c. Not the final word, but a meaningful data point that adds to the weight of evidence.

Key Findings

The paper reports that MOTS-c levels are reduced in ovarian cancer patients and exogenous MOTS-c inhibits OC cell proliferation, migration, and invasion. It also identifies USP7 as a deubiquitinase of LARS1 and shows that MOTS-c attenuates this interaction.

Limitations

The study lacks specific sample size details for human subjects and focuses primarily on in vitro and preclinical models, limiting direct clinical applicability.

PeptideVault Analysis

Highlighting the discovery of MOTS-c's anti-tumor effects in ovarian cancer and its potential as a novel therapeutic target.

MOTS-c

MOTS-c: A Promising New Player in Ovarian Cancer Treatment

Published: May 16, 2026 | Source: Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2024) | Category: MOTS-c

Overview

A recent study published in Advanced Science has uncovered a potential new therapeutic target for ovarian cancer (OC): the mitochondrial-derived peptide MOTS-c. This research highlights how MOTS-c can inhibit OC cell proliferation and migration by targeting specific cellular pathways, suggesting its role as a promising candidate for future clinical interventions.

Study Background

Mitochondria are not only energy-producing organelles but also play critical roles in signaling and maintaining cellular homeostasis through the release of various peptides. One such peptide is MOTS-c (mitochondrial open reading frame of the 12S rRNA C), which has been previously implicated in metabolic regulation and aging processes. However, its role in cancer progression was largely unknown until this recent study.

What the Research Found

The research team discovered that MOTS-c levels are significantly reduced in both serum and tumor tissues from OC patients compared to healthy controls. This reduction correlates with poorer patient prognosis. When exogenous MOTS-c is introduced into OC cells, it inhibits their proliferation, migration, and invasion capabilities while inducing cell cycle arrest and apoptosis.

Mechanistically, the study identified that MOTS-c interacts directly with LARS1 (Leucyl-tRNA synthetase 1), a protein known to play an oncogenic role in OC. By promoting LARS1 ubiquitination and subsequent proteasomal degradation, MOTS-c effectively suppresses its oncogenic function. Additionally, the study revealed that USP7 (Ubiquitin Specific Peptidase 7) acts as a deubiquitinase for LARS1, thereby stabilizing it. However, MOTS-c competes with USP7 to bind LARS1, thus attenuating this stabilization process.

What This Means for Peptide Users

While the findings are promising, it's important to note that this study primarily focuses on in vitro and preclinical models of OC. For peptide users interested in therapeutic applications, these results suggest a potential future role for MOTS-c or similar peptides in targeted cancer therapies. However, further research is necessary before clinical application can be considered.

Limitations and Caveats

The study lacks detailed information regarding the sample size used for human subjects, which limits its statistical power and generalizability to broader populations. Additionally, while preclinical models demonstrated a marked anti-tumor effect of MOTS-c without systemic toxicity, these findings need validation in larger animal studies and eventually in human clinical trials.

How This Compares to Previous Research

Previous research has highlighted the role of mitochondrial peptides like MOTS-c in metabolic regulation but did not specifically address their involvement in cancer progression. The current study builds upon this foundation by elucidating a novel mechanism through which MOTS-c can suppress OC growth, thereby bridging the gap between mitochondrial signaling and oncogenesis.

Our Analysis

The research provides compelling evidence for the potential of MOTS-c as a therapeutic agent against ovarian cancer. However, given its preliminary nature and focus on preclinical models, it is crucial to approach these findings with caution until further validation in human subjects is achieved. The study's detailed mechanistic insights offer valuable groundwork for future investigations into mitochondrial peptides' roles in cancer biology.

Key Takeaways

  • MOTS-c levels are reduced in ovarian cancer patients, correlating with poorer prognosis.
  • Exogenous MOTS-c inhibits OC cell proliferation and migration by targeting LARS1 via USP7 interaction.
  • The study highlights the potential of MOTS-c as a therapeutic target but requires further validation in clinical settings.

Original Source

Citation: Yin Yadong, Li Yujie, Ma Boyi et al. (2024). Mitochondrial-Derived Peptide MOTS-c Suppresses Ovarian Cancer Progression by Attenuating USP7-Mediated LARS1 Deubiquitination.. Advanced science (Weinheim, Baden-Wurttemberg, Germany). DOI: 10.1002/advs.202405620

Access: https://pubmed.ncbi.nlm.nih.gov/39321430/

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

Editor's Note

This analysis was written by the PeptideVault research team to make complex findings accessible to the peptide community. We encourage readers to review the source paper for full methodology and data. For more on MOTS-c, explore our research guides.

Citation

Yin Yadong, Li Yujie, Ma Boyi et al.. (2024). Mitochondrial-Derived Peptide MOTS-c Suppresses Ovarian Cancer Progression by Attenuating USP7-Mediated LARS1 Deubiquitination.. Advanced science (Weinheim, Baden-Wurttemberg, Germany). https://doi.org/10.1002/advs.202405620

View full text on PubMed

Related Papers

Mitochondrial-derived peptides: Antidiabetic functions and evolutionary perspectives.

Kal Satadeepa et al. · Peptides · 2024

Mitochondria-derived peptides in aging and healthspan.

Miller Brendan et al. · The Journal of clinical investigation · 2022

Mitochondrial-derived peptides in aging and age-related diseases.

Kim Su-Jeong et al. · GeroScience · 2021

Mitochondria-encoded peptide MOTS-c participates in plasma membrane repair by facilitating the translocation of TRIM72 to membrane.

Jia Hong et al. · Theranostics · 2024

The mitochondrial-derived peptide MOTS-c is a regulator of plasma metabolites and enhances insulin sensitivity.

Kim Su-Jeong et al. · Physiological reports · 2019

This content is derived from peer-reviewed research for educational purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider before using any peptide-based therapy.